Estrella Immunopharma, Inc. (ESLA) Financials

ESLA Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 3.7 million 8.9 million
Dec. 31, 2025 3.2 million 13.5 million
Sept. 30, 2025 3.5 million 13.4 million
June 30, 2025 3.0 million 9.1 million

ESLA Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -6.7 million 146714
Dec. 31, 2025 -177487 148360
Sept. 30, 2025 -727332 152421
June 30, 2025 -414879 159098

ESLA Net Income

No data available :(

ESLA Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 1.9 million - -
Dec. 31, 2025 1.4 million - -
Sept. 30, 2025 1.6 million - 4000
June 30, 2025 1.3 million - 4000

ESLA Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 42.1 million
Dec. 31, 2025 38.0 million
Sept. 30, 2025 37.1 million
June 30, 2025 36.2 million

ESLA Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 1.4 million 891789 -
Dec. 31, 2025 - 25414 587785 -
Sept. 30, 2025 - 4.2 million 648507 -
June 30, 2025 - 4.7 million 883727 -

ESLA Cost of Revenue

No data available :(

ESLA

Price: $0.95

52 week price:
0.78
3.15

Earnings Per Share: -0.34 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 49.1 million

Links: